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Introduction
Telomerase, a ribonucleoprotein enzyme complex consisting of 
an RNA component (Terc) and the reverse transcriptase catalytic 
subunit (TERT), adds telomere repeats (TTAGGG) onto chromo-
some ends, compensating for the erosion of protective telomeric 
ends that occurs as a normal consequence of cell division (1–4). 
TERT is expressed during embryonic development and in spe-
cific germline cells and stem cells in adults and, therefore, lim-
its the levels of active telomerase in these cell types (5). In more 
than 90% of human cancers, transcriptional derepression of 
TERT is thought to lead to telomerase reactivation by the recon-
stitution of telomerase activity (5–7). While the maintenance 
of telomere length in cancer cells is thought to be the primary 
function of reactivated telomerase, growing evidence hints at 
telomere-independent functions of this enzyme (8, 9). These 
functions include regulation of mitochondrial activity (10–12), 
cell proliferation and apoptosis (13–15), WNT/β-catenin signaling 
(16), NF-κB signaling (17), and DNA-damage repair (18–21), all of 
which may play roles in oncogenesis. Despite these studies from 
various labs, the molecular mechanism of how telomerase reacti-
vation imparts cancer cells with the many properties, collectively 
referred to as the “hallmarks of cancers,” is not well understood.
MYC is a commonly overexpressed oncogene that is a central 
regulator of proliferation, directly modulating the transcription of 
key genes involved in cell cycle regulation and metabolism as well 
as DNA/RNA synthesis and translation (22–24). Expression of 
MYC target genes is dependent on MYC’s dimerization with MAX 
(25) and subsequent binding to chromatin, mainly through the rec-
ognition of a DNA-binding motif (E-box) in a permissive chroma-
tin context (23, 24, 26). Another key aspect affecting the function 
of MYC is its binding to transcriptional cofactors, which affects its 
activity as a transcriptional activator or repressor and its ability to 
bind to chromatin (27–29). MYC is targeted for rapid degradation 
under physiological conditions (30), and this process is tightly 
regulated by sequential posttranslational modifications, such as 
phosphorylation at the key residues, serine 62 (S62) and threonine 
58 (T58) (31, 32). Mutations at these residues are often observed 
in Burkitt’s lymphomas, while the aberrant phosphorylation status 
of T58 and S62 is observed in all MYC-driven tumors (33, 34). Sev-
eral oncogenic pathways converge to regulate MYC stability, and 
the deregulated levels of MYC throughout the cell cycle contrib-
ute to tumor initiation and progression (32, 35). MYC mRNA has a 
short half-life and is targeted by several miRNAs, which control its 
expression levels (36, 37). Hence, identifying novel cofactors that 
regulate MYC protein stability would provide a unifying mecha-
nism accounting for enhanced MYC function in cancers.
Here, we explored the possibility that reactivated TERT, seen 
in parallel with MYC hyperactivation in the vast majority of can-
cers, may possess unexpected telomere-independent functions. 
Constitutively active MYC and reactivated telomerase often coexist in cancers. While reactivation of telomerase is thought 
to be essential for replicative immortality, MYC, in conjunction with cofactors, confers several growth advantages to cancer 
cells. It is known that the reactivation of TERT, the catalytic subunit of telomerase, is limiting for reconstituting telomerase 
activity in tumors. However, while reactivation of TERT has been functionally linked to the acquisition of several “hallmarks 
of cancer” in tumors, the molecular mechanisms by which this occurs and whether these mechanisms are distinct from 
the role of telomerase on telomeres is not clear. Here, we demonstrated that first-generation TERT-null mice, unlike Terc-
null mice, show delayed onset of MYC-induced lymphomagenesis. We further determined that TERT is a regulator of MYC 
stability in cancer. TERT stabilized MYC levels on chromatin, contributing to either activation or repression of its target genes. 
TERT regulated MYC ubiquitination and proteasomal degradation, and this effect of TERT was independent of its reverse 
transcriptase activity and role in telomere elongation. Based on these data, we conclude that reactivation of TERT, a direct 
transcriptional MYC target in tumors, provides a feed-forward mechanism to potentiate MYC-dependent oncogenesis.
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To extend the relevance of our findings to human disease, 
we generated P493 cells, a human lymphoma cell line, with sta-
ble knockdown of TERT (shTERT1, shTERT2, and shTERT3), 
Terc (shTerc), or control (shControl) or ectopic expression of cat-
alytically active TERT (TERT WT) or catalytically inactive TERT 
(TERT DN). As observed with murine lymphoma cells in vivo, 
TERT-depleted P493 cells showed reduced tumorigenicity com-
pared with that of control cells and Terc-depleted P493 cells, as 
reflected by the increased survival of recipient mice (P < 0.01 
for shTERT vs. shControl or shTerc) (Figure 1E). Since shTERT3 
targets the 3′UTR region of TERT transcript, we could reexpress 
TERT in these cells. When xenografted in mice, we observed a par-
tial, but significant, rescue in survival (Figure 1E). Taken together, 
these results suggest that TERT, unlike Terc, is essential for MYC-
driven lymphoma progression. Given that Terc loss did not affect 
TERT levels in EμMYC murine B cells (Supplemental Figure 1D) 
and shTERT did not cause significant telomere attrition under 
assayed conditions (Supplemental Figure 1E), these data imply 
that TERT subunit functions as a cofactor of MYC independent 
from Terc and, hence, independent from its function on telomeres.
Tert–/– mice, but not Terc–/– mice, display delayed onset of MYC-
driven lymphomas. In order to validate our findings in a defined 
genetic background, we crossed EμMYC mice with Tert and Terc 
heterozygous (Tert+/–) mice. We found that the lack of TERT sig-
nificantly increased the tumor-free survival of the mice. EμMYC 
Tert–/– mice had a median tumor-free survival of 237 days, as com-
pared with 116 days for EμMYC Tert+/+ mice (P = 0.01) (Figure 2A). 
On the contrary, lack of Terc had no effect on lymphoma progres-
sion and mouse survival (Figure 2B). This is consistent with pre-
vious reports that EμMYC-driven lymphomagenesis is unaffected 
by homozygous deletion of Terc in early generations, in which Terc 
deletion has not yet led to critical telomere shortening (43).
In a group of age-matched, 12-week-old littermates, EμMYC 
Tert+/+ mice had higher Myc levels than EμMYC Tert+/– and EμMYC 
Tert–/– mice (Figure 2C). Specifically, 6 of 17 EμMYC Tert+/+ mice 
(35.2%) had palpable tumors, compared with only 1 of 15 EμMYC 
Tert+/– mice (6.67%) and none of the EμMYC Tert–/– mice (0 of 15, 
0%). Consistently, age-matched EμMYC Tert+/+ mice had a higher 
wbc count and enlarged spleens compared with EμMYC Tert–/– 
mice (Figure 2D). Histologically, the spleens of EμMYC Tert+/+ 
mice showed hypercellularity, with highly proliferative (Ki67+) 
B cells (B220+) distributed throughout the red and white pulp of 
the spleen (Figure 2E), consistent with what has been reported 
previously (42). In contrast, the spleens of EμMYC Tert–/– mice had 
fewer nonproliferative (Ki67–) B cells (B220+) present in well-de-
fined germinal centers, which is morphologically similar to the 
spleen of a healthy mouse (Figure 2E). Importantly, telomere 
lengths were similar in tumors from EμMYC Tert+/+ and EμMYC 
Tert–/– mice (Supplemental Figure 2A), and we did not observe 
telomere-associated DNA damage foci in EμMYC Tert–/– cells 
(Supplemental Figure 2B). Consistent with the findings that first- 
generation Tert-null mice do not display telomere dysfunction 
(44), these results indicate that the delay in tumor onset observed 
in EμMYC Tert–/– mice is unlikely to be associated with telomeric 
dysfunction (Supplemental Figure 2). These data clearly delineate 
the role of TERT as a key regulator of MYC function, independent 
of its function as a telomerase component.
We report that TERT is required for maintaining MYC stability 
and promoting optimal binding of MYC to its chromatin targets in 
cancer cells. Furthermore, we show that TERT directly contributes 
to MYC-dependent functions, including regulation of glycolytic 
genes, cell proliferation, and in vivo pretumoral cellular hyperpro-
liferation and tumorigenesis. We propose that the reactivation of 
TERT, a direct MYC target in human cancers (38), may provide a 
feed-forward mechanism to potentiate the oncogenic properties 
of MYC, especially in cancer cells, which require rewiring of their 
growth and metabolic programs in order to gain a limitless poten-
tial to grow and proliferate.
Results
TERT, but not Terc, affects MYC-dependent oncogenesis. Reactiva-
tion of TERT occurs in parallel with MYC in a vast majority of can-
cers, and pattern-matching algorithms in microarray data sets have 
revealed that the telomerase transcriptional response strongly 
resembles that of MYC (39). In order to assess the functional inter-
play between TERT and MYC, we made use of the EμMYC murine 
model, which contains a Myc-IgH translocation, characteristic of 
Burkitt’s lymphoma (40, 41). In this model, the Myc transgene 
is expressed in the B lymphoid cells and drives B cell hyperpro-
liferation and subsequently, lymphoma (42). In EμMYC mice, 
MYC and TERT levels were markedly elevated (Supplemental 
Figure 1A; supplemental material available online with this arti-
cle; doi:10.1172/JCI79134DS1), specifically in the B cells isolated 
from the spleens and tumors but not from other tissues (Figure 
1A). We knocked down TERT (shTERT-A and shTERT-B) in pri-
mary EμMYC lymphoma cells and found a significant reduction 
in viability in vitro, as compared with that in control cells (shCon-
trol) (Supplemental Figure 1B). This could be rescued, at least in 
part, by ectopic expression of human TERT (shTERT-A + TERT, 
shTERT-B + TERT), indicating the specificity of the shRNA used 
in this study (Supplemental Figure 1B). Importantly, TERT knock-
down in WT mouse B cells only had a minimal effect on cell viabil-
ity in vitro, suggesting a possible increased dependence of cancer 
cells on TERT (Supplemental Figure 1C). To validate our findings in 
vivo, we xenografted the primary lymphoma cells described above 
(shControl, shTERT-A, shTERT-B, TERT, shTERT-A + TERT, 
shTERT-B + TERT cells) into syngeneic recipient mice. To fur-
ther dissect the effects of the telomerase components, TERT and 
Terc, both of which are necessary for telomerase activity, we also 
included Terc-depleted (shTerc) cells. The tumor-free survival of 
recipient mice xenografted with shTERT-A or shTERT-B cells was 
significantly prolonged, as compared with that of recipient mice 
xenografted with shTerc and shControl cells (Figure 1B). Notably, 
the tumor-free survival of recipient mice xenografted with either 
shControl or shTerc cells was similar (P = 0.07), in agreement with 
findings from a previous report (43). As observed in vitro (Supple-
mental Figure 1B), the ectopic expression of human TERT in vivo 
rescued the reduction in tumorigenicity caused by TERT knock-
down, and the recipient mice xenografted with shTERT-A + TERT 
and shTERT-B + TERT cells had similar tumor-free survival to 
that of shControl mice (Figure 1B). Accordingly, at 4 weeks after 
xenograft, the mice xenografted with TERT-depleted cells had 
markedly reduced disease burden, as evidenced by significantly 
lower lymph node/tumor (Figure 1C) and spleen (Figure 1D) sizes.
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its chromatin binding and transcriptional activity, we carried out 
genome-wide ChIP sequencing (ChIP-Seq) and microarray-based 
gene expression profiling. The overall genomic distribution of 
MYC peaks was unaffected by either TERT or Terc depletion in 
P493 cells (Figure 3A) or by Tert deletion in EμMYC-derived 
tumors (Figure 3B), with the majority of peaks occurring within 
approximately 500 bp upstream or downstream of the transcrip-
tion start site (Figure 3, A and B). Nonetheless, TERT depletion 
TERT globally affects MYC association with target promoters and 
regulates MYC-dependent gene expression. During early lymphoma-
genesis, MYC binds to target promoters, modulating their expres-
sion both positively and negatively (23, 24). At later stages, MYC 
levels increase, and it targets all active promoters and enhancers, 
a phenomenon that has been dubbed “invasion” and which con-
tributes to MYC-driven transcriptional amplification (23, 24, 45, 
46). To assess whether TERT cooperates with MYC by affecting 
Figure 1. Effect of acute depletion of TERT on MYC-driven lymphomas in vivo. (A) Western blots showing levels of TERT, MYC, and actin in different 
tissues of EμMYC mice. (B) Kaplan-Meier survival analysis for mice xenografted with shControl, shTERT-A, shTERT-B, ectopic TERT, shTERT-A + ectopic 
TERT, shTERT-B + ectopic TERT, or shTerc EμMYC primary lymphoma cells. P < 0.01, shControl vs. shTERT-A and shTERT-B; P > 0.05, shControl vs. shTerc, 
TERT, shTERT-A + TERT, and shTERT-B + TERT. Weights of (C) tumors and (D) spleens of mice in B 1 month following transplant. Each dot represents an 
individual recipient mouse. The horizontal bars represent the mean. (E) P493 cells infected with shControl, shTERT1, shTERT2, shTERT3, TERT WT, TERT 
DN, shTERT3 + TERT WT, shTERT3 + TERT DN, and shTerc were xenografted into SCID recipient mice. P < 0.01, shControl vs. shTERT1, shTERT2, shTERT3; 
P > 0.05, shControl vs. shTERC; P < 0.01, shTERT3 vs. shTERT3 + TERT WT and shTERT3 + TERT DN. Survival analysis was carried out using the Kaplan-
Meier method with log-rank test. The number of animals is indicated by the graph. One-way ANOVA with Dunnett’s multiple comparison test was used to 
compare differences between the various groups and shControl. *P < 0.05, **P < 0.01, versus control.
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Figure 2. Homozygous deletion of Tert delays MYC-driven lymphomagenesis in vivo. (A) Kaplan-Meier curves showing the tumor-free survival of EμMYC 
Tert+/+, EμMYC Tert+/–, and EμMYC Tert–/– mice. (B) Kaplan-Meier curves showing the tumor-free survival of EμMYC Terc+/+, EμMYC Terc+/–, and EμMYC Terc–/– mice. 
(C) MYC levels in spleen B cells from 12-week-old EμMYC Tert+/+ (n = 3), EμMYC Tert+/– (n = 4), and EμMYC Tert–/– mice (n = 5). (D) wbc counts, spleen weights, and 
tumor weights in 12-week-old EμMYC Tert+/+, EμMYC Tert+/–, and EμMYC Tert–/– mice. Each dot represents an independent mouse. The horizontal bars represent 
the mean. (E) Representative immunohistochemistry images (original magnification, ×10), showing B220 and Ki67 staining in EμMYC Tert+/+, EμMYC Tert+/–, and 
EμMYC Tert–/– spleens. Spleens from at least 3 mice of each genotype were analyzed. One-way ANOVA with Dunnett’s multiple comparison test was used to 
compare differences between the various genotypes and EμMYC Tert+/+. P < 0.05, P < 0.01, P > 0.05, vs. EμMYC Tert+/+.
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ectopically expressing TERT WT and TERT DN upregulated the 
same MYC targets (Figure 4E). P493 cells express exogenous 
MYC under negative tetracycline regulation and EBNA under 
positive estradiol regulation, and these cells can be grown under 
high-MYC (FBS 10%) and low-MYC (FBS 10%, tetracycline, 
and estradiol) conditions (23). We tested whether the observed 
TERT-mediated regulation of MYC function was similar under 
high- and low-MYC conditions. Our data demonstrate that TERT 
depletion preferentially affected cells with high-MYC levels, 
while TERT was dispensable for the proliferation of cells with 
low-MYC levels (Figure 4F). Importantly, the degree of TERT 
knockdown was similar under both high- and low-MYC condi-
tions (Supplemental Figure 4, A and B).
TERT interacts with and regulates MYC protein ubiquitination 
and stability. The results presented so far show that TERT regu-
lates MYC-dependent processes. To understand the molecular 
basis of this observation, we first analyzed Myc mRNA and MYC 
protein abundance upon perturbation of TERT or Terc levels. 
Knocking down TERT reduced MYC steady-state levels, while 
Terc knockdown had no effect, as compared with that of shControl 
(Figure 5A). Further, the reexpression of TERT WT or TERT DN 
could rescue the steady-state levels of MYC (Figure 5A). Accord-
ingly, overexpressing TERT WT or TERT DN increased MYC 
protein abundance (Figure 5B). As a control, we also assessed 
the levels of MYC upon TERT knockdown in a telomerase- 
negative cell line, VA13. First, to test the functionality of shTERT 
in VA13, we overexpressed TERT and subsequently, knocked 
down TERT via shRNA (Supplemental Figure 5A, left panel). By 
real-time PCR, we first proved that shTERT1 and shTERT2 were 
functional in reducing TERT levels in VA13 cells. Further, we 
could not detect any differences in the steady-state levels of MYC 
upon TERT knockdown (Supplemental Figure 5A, right panel). 
Given that Myc mRNA levels were not altered by varying TERT or 
Terc expression (Figure 4E and Figure 5C), we can conclude that 
TERT, but not Terc, regulates MYC abundance posttranscription-
ally. We also assessed the levels of MYC in EμMYC B cells fol-
lowing TERT knockdown and found a similar reduction in MYC 
levels, which could be rescued by the expression of human TERT 
(Figure 5D). Since TERT had a dramatic effect on steady-state 
levels of MYC, we sought to determine whether TERT could inter-
act with MYC independent of MYC levels. We coimmunoprecip-
itated MYC and TERT in high-MYC– and low-MYC–expressing 
P493 cells as well as in nontransformed hepatocyte (MIHA) cells, 
which express low-MYC/TERT levels. Interestingly, we could 
detect the interaction only in high-MYC cells (Figure 5E and Sup-
plemental Figure 5B). We also found that this interaction was lost 
upon TERT knockdown (Supplemental Figure 5C). It is, however, 
important to note that the levels of MYC itself were reduced in 
low-MYC conditions and upon TERT knockdown (Supplemental 
Figure 5), while Terc knockdown had no effect on this interaction 
(Supplemental Figure 5). To further characterize the MYC-TERT 
interaction in a chromatin context, we investigated TERT occu-
pancy at known MYC target sites by ChIP. We found that TERT 
was bound to these promoters in P493 cells and its binding was 
reduced by specific TERT knockdown (siTERT) (Figure 5F). The 
binding of MYC to the same promoters was also impaired under 
similar conditions (Figure 5G), reiterating the importance of 
resulted in an overall reduction in the affinity of MYC binding at 
promoter regions (Figure 3, C–E). The binding profiles for MYC to 
specific promoters involved in cell metabolism, cell cycle regula-
tion, and RNA transcriptional and posttranscriptional regulation 
are shown as examples in Figure 3, D–F, and Supplemental Figure 
3, A and B. We validated selected ChIP-Seq targets by quantita-
tive PCR (qPCR) in both P493 cells (Supplemental Figure 3, C and 
D) and EμMYC Tert+/+ and EμMYC Tert–/– B cells (Supplemental 
Figure 3E). Consistent with MYC function, its depletion from tar-
get sites, upon reduction of TERT levels, resulted in a concomi-
tant loss of POL2 at these regions (Supplemental Figure 3E). To 
ensure that the loss of MYC binding to its promoters upon TERT 
knockdown was not due to a general or nonspecific effect, we also 
assessed the effect of shTERT on the binding of another transcrip-
tion factor, NF-YA, to its target promoters in P493 cells. In contrast 
to the reduction of MYC binding to its target promoters, we did not 
observe any significant effect of TERT knockdown on the binding 
of NF-YA (Supplemental Figure 3F).
Finally, we coanalyzed the genome-wide MYC binding data 
obtained from ChIP-Seq and the global gene expression changes 
from microarray profiling of TERT-depleted P493 cells. Genes 
involved in translation and RNA processing and metabolism were 
mainly affected, both positively and negatively (Figure 3, G and 
H). This is not unexpected, as MYC-mediated transcriptional 
outcomes are dependent on the association with other cofactors, 
such as MIZ-1 (24, 25, 47, 48). The altered expression of selected 
MYC-regulated genes in B cells from additional age-matched 
EμMYC Tert+/+, EμMYC Tert+/–, and EμMYC Tert–/– mice (Supple-
mental Figure 3G), as well as following TERT knockdown in P493 
cells (Supplemental Figure 3, H and I) and EμMYC B cells (Sup-
plemental Figure 3J), was validated by qPCR. Notably, consistent 
results were obtained with independent shRNAs and could be res-
cued by TERT overexpression (Supplemental Figure 3, H–J). While 
we observed a significant enrichment in MYC binding and tran-
scriptional increase in some of these ribosomal components, this 
was also the case for RNA polymerase II–driven genes (49–51). As 
such, we believe that, in cancer cells, the effect of MYC stabiliza-
tion by TERT affects the expression numerous MYC-dependent 
genes, including ribosomal components.
TERT regulates MYC-dependent cellular processes. Having 
shown that the telomerase TERT component affects MYC-
driven oncogenesis and the binding of MYC to its target pro-
moters, we next sought to investigate whether TERT affects 
MYC-dependent cellular processes. MYC overexpression has 
been known to confer tumorigenicity, in part, by reprogramming 
various metabolic pathways, thus sustaining increased prolifer-
ation and growth rates (52). A previous microarray-based gene 
expression profiling of cancer cells showed that telomerase regu-
lates several genes in the glycolytic pathway (53). In agreement, 
we found that knocking down TERT in P493 cells reduced the 
expression of MYC-regulated glycolytic genes (Figure 4A) as 
well as proliferation (Figure 4B). When these cells were reconsti-
tuted with MYC, their gene expression and proliferation defects 
were rescued (Figure 4, A and B). Similar reductions in cell via-
bility (Figure 4C) and the expression of MYC-regulated genes 
(Figure 4D) were observed by reducing either MYC (siMYC) or 
TERT (siTERT) levels in primary patient cells. Conversely, cells 
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TERT for MYC binding to chromatin. Colocalization of TERT and 
MYC was finally confirmed by sequential ChIP (Figure 5H).
We then embarked on making recombinant TERT and MYC 
proteins to map the domains of interaction. Like most research-
ers in the field, we were unable to make recombinant full-length 
human TERT, as it is highly insoluble and highly impure (and part 
of the reason structural determination of the entire human com-
plex has not yet been achieved). Since MYC could be purified and 
its domains could be analyzed, we made various MYC deletion 
constructs and found that the first 110 amino acids of MYC (Sup-
plemental Figure 5D), encompassing MYC box I (MBI), could 
interact with TERT (Supplemental Figure 5E). Indeed, the recom-
binant 1–110 MYC mutant, but not the rest of the recombinant 
MYC (MYC amino acids 98–439) protein, interacted with TERT in 
mammalian cells (Supplemental Figure 5F). Importantly, a mutant 
of MYC, which lacks the TERT interaction domain, when ectopi-
cally expressed with TERT, could not activate MYC target genes to 
the degree seen in cells expressing TERT and WT MYC (Supple-
mental Figure 5G). We also tried to map the domain of TERT that 
is important for binding MYC; however, all the deletion mutants 
interacted with endogenous MYC, as can be seen in Supplemen-
tal Figure 5H, suggesting that multiple domains of TERT may be 
required for this binding.
The results presented so far demonstrate that TERT interacts 
with MYC, stabilizing its protein abundance and its specific bind-
ing to its target promoters on chromatin. To understand the molec-
ular basis of this observation, we next treated cells with cyclohexi-
mide for various time periods to block translation and determined 
the half-life of MYC upon TERT or Terc knockdown. Knockdown 
of TERT had a dramatic effect on the stability of MYC, while Terc 
knockdown showed no effect (Figure 6A). To rule out nonspecific 
effects of shRNA, we used two additional independent shRNAs 
to knockdown TERT and found a similar reduction in MYC half-
life (Supplemental Figure 6A). Similar reductions in MYC stability 
were observed in primary EμMYC B cells following TERT knock-
down (Figure 6B). As MYC is degraded, to a large extent, by the 
proteasome pathway, we wanted to check whether inhibiting the 
proteasome in TERT-depleted cells would restore the levels of 
MYC to those in the control cells. In TERT-depleted P493 cells 
and EμMYC B cells, proteosomal inhibition with MG132 restored 
MYC to similar levels as those in control cells (Figure 6, C and D). 
These results suggest that TERT regulates MYC protein stability.
MYC stability is tightly regulated by a sequential cascade 
of phosphorylation and dephosphorylation events. The two key 
steps in this process are a priming phosphorylation event on S62, 
followed by subsequent phosphorylation at T58 by GSK3β, a key 
event that leads to rapid proteasomal degradation (33, 54–57). 
Indeed, the levels of pT58-phosphorylated MYC decreased in 
cells ectopically expressing either TERT WT and TERT DN (Fig-
ure 6E). We also checked the stability of MYC with the T58A muta-
tion upon TERT depletion and could not detect any difference in 
its stability (Supplemental Figure 6B). We further performed a 
gene expression analysis in control and TERT-depeleted cells 
ectopically expressing WT MYC or MYC T58A. When ectopically 
expressed, MYC T58A very efficiently activated downstream MYC 
targets (e.g., EIF2A and NCL), and the degree of their transcrip-
tional activation was not reduced by TERT knockdown (Supple-
mental Figure 6C). The exclusion of GSK3β from interacting with 
MYC/MAX and phosphorylating MYC on T58 is a plausible mech-
anism of how TERT reactivation in cancers could promote MYC 
stabilization on chromatin. We tested this hypothesis and showed 
that reducing TERT levels enhanced the interaction between 
GSK3β and MYC (Figure 6F), and this resulted in reduced MYC 
levels. Since GSK3β-mediated phosphorylation of MYC regulates 
its ubiquitination and hence, its stability, we further assessed the 
levels of MYC ubiquitination following TERT knockdown or over-
expression. Knockdown of TERT enhanced the ubiquitination of 
MYC (Figure 6G and Supplemental Figure 6D). Conversely, the 
overexpression of TERT decreased the ubiquitination of MYC 
(Figure 6H). It is important to note that the effect of TERT on 
MYC stability is mediated via MBI, the domain that is known to 
directly regulate MYC protein stability (58) and contains residue 
T58. Knocking down TERT showed no effect on the ubiquitination 
of a MYC deletion mutant that is unable to interact with TERT 
(Supplemental Figure 6E). In summary, we propose that the effect 
of TERT on MYC is mediated by TERT’s ability ability to toggle 
the interaction between MYC and GSK3β, which is well known to 
control MYC stability.
Discussion
Tumorigenesis is a complex process involving the activation of 
oncogenes and inactivation of tumor suppressors in order to 
sustain proliferative signaling, evade cell death, enable repli-
cative immortality, induce angiogenesis, and activate invasion 
and metastasis. Telomerase reactivation and/or TERT upregula-
tion has been observed in more than 90% of human cancers (6) 
and has been shown to correlate with MYC overexpression (59). 
Although preventing replicative “crisis” due to telomere attrition 
is the primary recognized function of telomerase (3, 60), evidence 
from several leading laboratories has recently suggested that this 
Figure 3. Genome-wide effect of TERT on MYC binding to target promoters and expression of MYC-regulated target genes. MYC ChIP-Seq was performed 
in (C) P493 shControl, shTERT1, and shTerc or EμMYC Tert+/+ and EμMYC Tert–/– cells. (A and B) Peak profile centering on the transcriptional start site. Peaks 
were normalized to a width of 300 bp, and the frequency of binding events (1 equals all events) was calculated at each distance to the transcriptional 
start site. (C and E) Read density profile plots focusing on the transcriptional start site of MYC-bound promoters. Read densities at all promoters bound 
by MYC within 500 bp around the transcriptional start site in (C) P493 shControl, shTERT1, and shTerc or (E) EμMYC Tert+/+ and EμMYC Tert–/– cells were 
calculated and plotted as a heat map of normalized, background subtracted reads per sample. The black line indicates the transcriptional start site. (D and 
F) Representative examples of MYC binding to selected promoters. RPM, reads per million. (G) Transcriptional outcome of altered MYC binding upon loss 
of TERT. Bound and differentially expressed promoters were identified in P493 shControl and P493 shTERT1 cells. The change in MYC binding in shTERT1 
is indicated on the x axis as the log2-fold change (normalized, background subtracted read densities within 500 bp upstream and downstream of the tran-
scriptional start site around the transcriptional start site). Changes in expression are represented as normalized log2-fold change values of the respective 
genes on the y axis. The blue line is a linear smooth with a 0.95 confidence interval, indicating the general trend of the data set. (H) Enriched GO categories 
of bound and differentially expressed promoters, as indicated in G. The red line indicates a q value of 0.01, as reported by DAVID.
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We demonstrate that the TERT subunit of telomerase is responsi-
ble for this function, which is independent of its role on telomeres. 
While it was well known that TERT is a direct target of MYC (38, 
63, 64), we show here that TERT, in turn, is required to sustain 
MYC stability, thereby affecting MYC-dependent transcriptional 
programs and oncogenic properties. We demonstrate that, in the 
EμMYC model, high levels of TERT driven by MYC are essential 
enzyme possesses properties that directly or indirectly impact 
other biological processes necessary for transformation, indepen-
dently from its role on telomeres (12, 61, 62). However, the mech-
anism(s) by which these noncanonical activities of telomerase 
contribute to oncogenic signaling are still poorly understood. 
Here, we found that telomerase can directly regulate oncogenesis 
by regulating MYC-dependent transcription and, hence, function. 
Figure 4. Phenotypic effects of TERT inhibition or depletion on MYC-dependent processes. (A) Gene expression analysis of the indicated genes in P493 
cells infected with vector, shTERT1, and shTERT1 + MYC (n = 3). **P < 0.01 vs. vector; #P < 0.05, ##P < 0.01 vs. shTERT, 1-way ANOVA with Tukey’s multiple 
comparison test. (B) Cell cycle profile of P493 cells infected with the indicated vectors. The cells were stained with propidium iodide and analyzed by FACS 
and FlowJo software for cell cycle phase distribution (n = 3). (C) Relative viability of independent primary patient cells (indicated on x axis) following MYC or 
TERT knockdown (n = 3 for each patient sample). AML, acute myeloid leukemia; B-ALL, B cell acute lymphoid leukemia. (D) Gene expression in primary patient 
samples (indicated on x axis) following MYC or TERT knockdown (n = 3 for each patient sample). (C and D) *P < 0.05, **P < 0.01, vs. siControl, Student’s t test. 
(E) Gene expression analysis in P493 cells infected with vector, TERT WT, and TERT DN (n = 3). *P < 0.05, **P < 0.01, #P > 0.05, vs. vector, Student’s t test. (F) 
Cell proliferation in P493 cells with knockdown of TERT and Terc under high-MYC and low-MYC conditions (n = 3).
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Figure 5. TERT affects MYC steady-state levels. (A) Western blots showing levels of indicated proteins upon knockdown with shControl, shTERT1, 
shTERT2, shTERT3, and shTerc and upon reexpression of TERT WT and TERT DN in shTERT3 cells. (B) Western blots showing levels of indicated proteins 
upon TERT WT and TERT DN ectopic expression. TT, TERT+Terc. (C) Gene expression analysis of MYC in P493 cells infected with shControl, shTERT, and 
shTerc. #P > 0.05, compared with shControl, Student’s t test. (D) Western blot showing steady-state levels of MYC following TERT knockdown in EμMYC B 
cells using 2 independent shRNAs and in cells with reexpression of human TERT. (E) Coimmunoprecipitation between endogenous MYC and TERT in the 
cells infected with shControl, shTERT, or shTerc. (F and G) ChIP using antibodies against TERT and MYC, followed by qRT-PCR with primers specific for gene 
promoters containing MYC-binding sites in P493 siControl and siTERT cells. (H) Sequential ChIP was performed in P493 cells. ChIP was carried out first 
with antibody against MYC followed by antibody against either TERT or IgG as indicated. For the Western blots, representative images of n = 3 indepen-
dent experiments are shown. *P < 0.05, compared with sh/siControl, Student’s t test.
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Figure 6. TERT regulates MYC half-life and ubiquitination. (A and B) Western blots showing MYC levels upon TERT or Terc knockdown following cyclo-
heximide (CHX) treatment for indicated time points in P493 cells and EμMYC B cells. UT, untreated. (C and D) Western blots in P493 and EμMYC B cells 
showing the levels of MYC, TERT, and actin upon TERT knockdown, with and without MG132 treatment (10 μM, 2 hours). (E) Western blots showing 
levels of indicated proteins upon vector, TERT WT, and TERT DN expression. (F) Coimmunoprecipitation between endogenous MYC and GSK3β in cells 
infected with shRNA against control (–) or TERT (+) and immunoblotting with indicated antibodies. (G) 293T cells were transfected with HA-MYC and 
His-ubiquitin, along with shControl or shTERT1. 48 hours after transfection cells were harvested, immunoprecipitated with Ni-NTA beads, and Western 
blotted with HA. (H) In vivo MYC ubiquitination assay in cells transfected with control or TERT shRNAs, along with HA-ubiquitin. Immunoprecipitation 
and immunoblotting from lysates or immunoprecipitated material were performed by using indicated antibodies. For the Western blots, representa-
tive images of n = 3 independent experiments are shown.
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a telomere-independent role of TERT (distinct from Terc) in cancer 
initiation or progression in vivo. This is a very significant addition 
in itself, since it proves for what we believe to be the first time that 
TERT and Terc activities can be segregated, especially in transcrip-
tional regulation and cancer development, in vivo. These studies 
also show that the biochemical functions of TERT, unlike those 
of Terc, in cancer are not synonymous with telomerase activity. A 
model based on our findings is summarized in Figure 7. We believe 
that our study is the first genetic demonstration that TERT activity 
drives cancer progression independent of its roles in telomerase 
holoenzyme activity and that this could be the prime reason why 
TERT reactivation is seen in over 90% of human cancers.
Methods
Antibodies and reagents. The antibodies used for Western blots are as 
follows: anti-TERT (Epitomics); anti-MYC (sc-764; sc-40; A-14) and 
anti-MAX (sc-197) (Santa Cruz Biotechnology); anti-MYC (phospho 
S62) and anti-MYC (phospho T58) (Abcam); anti-GSK3β (BD Bio-
sciences); and anti–β-actin (Sigma-Aldrich) (see complete unedited 
blots in the supplemental material). TERT WT–, TERT DN–, and 
TERT+Terc-overexpression vectors were generated in-house (17). 
HA-ubiquitin and HIS-ubiquitin plasmids were a gift from James Chen 
(University of Texas Southwestern Medical Center, Dallas, Texas, 
USA). Sequences for human shTERT (shTERT1, shTERT2, shTERT3) 
and mouse TERT (shTERT-A, shTERT-B) are listed in Supplemen-
tal Table 1. The antibodies used for ChIP are as follows: anti-MYC 
(sc-764), anti–NF-YA (sc-10779), anti-POL2 (sc-899), and rabbit con-
trol IgG (sc-2027) (Santa Cruz Biotechnology) and anti-TERT for ChIP 
(Epitomics). The antibodies used for immunofluorescence are as fol-
lows: TRF2 (05-521, Millipore) and histone H2A.X (phospho S139) 
(ab81299, Abcam). The reagents used are as follows: tetracycline 
(0.1 μg/ml; Sigma-Aldrich); glucose (25 mM; Sigma-Aldrich); galactose 
(25 mM; Sigma-Aldrich); estradiol (1 μM, Sigma-Aldrich); cyclohexim-
ide (15 μg/ml, Sigma-Aldrich).
Cell culture and proliferation assays. P493 cells were a gift from the 
Amati lab (Center for Genomic Science, Fondazione Istituto Italiano 
di Tecnologia, Milan, Italy) and were maintained in RPMI medium 
1640 supplemented with 10% FBS, penicillin, and streptomycin. 
293T cells were purchased from ATCC, and VA13 cells were generated 
in-house. Both cell lines were maintained in DMEM medium sup-
plemented with 10% FBS, penicillin, and streptomycin. Proliferation 
assays were performed by seeding equal numbers of cells and count-
ing them every day using a trypan blue exclusion assay and a Bio-Rad 
TC-20 automated cell counter. Cell viability was determined by seed-
ing equal numbers of cells and measuring ATP content with a Cell-
Titer Glo Luminescent Cell Viability Assay Kit (Promega) 5 days later. 
For low-MYC expression, cells were cultured in 0.1 μg/ml tetracycline 
and 1 μM estradiol for 72 hours. EμMYC B cells and lymphomas were 
maintained as previously described (70, 71).
RNA interference and real-time qPCR. siRNAs against TERT tran-
script, MYC, and BRG1 were purchased from Dharmacon. siRNA was 
transfected into P493 cells in Optimem using Lipofectamine RNAi 
Max (Invitrogen) according to the manufacturer’s protocol and into 
primary human leukemia and lymphoma cells by electroporation using 
the Neon Transfection System (Invitrogen). For gene expression stud-
ies, total RNA was extracted with Trizol (Invitrogen) and purified using 
the RNeasy Mini Kit (Qiagen). 1 μg RNA was added as a template to 
for lymphomagenesis and that this function of TERT is indepen-
dent of its role on telomere length. Hence, this is the first study to 
our knowledge to experimentally demonstrate that a feed-forward 
transcriptional loop between MYC and TERT exists in cancers and 
that this loop is functionally critical for oncogenesis. It was previ-
ously shown that augmenting telomerase levels altered the rates 
of MYC-induced papillomatosis in a murine model (65); however, 
a mechanism accounting for the possible cooperation between 
MYC and telomerase was not described. Here, we propose a func-
tional role for the MYC-activated transcription of TERT, show-
ing that TERT is required for regulating MYC ubiquitination and 
stabilization of MYC and its binding to its target gene promoters. 
Although transcriptional regulation by telomerase was previously 
documented, it was thought that this requires the recruitment 
of the chromatin modifier, BRG1 (16). Our study brings to light 
a mechanism of direct transcriptional regulation by TERT, sug-
gesting that TERT can modulate transcription without evoking 
chromatin modifiers, like BRG1 (Supplemental Figure 7, A and B), 
but by controlling MYC stability. This, therefore, is a fundamental 
advancement in the way that we understand TERT function and 
transcription. Using a number of primary leukemia samples (acute 
myeloid leukemia and B cell acute lymphoid leukemia), we doc-
ument, for the first time to our knowledge, that inhibiting TERT 
regulates the expression of MYC target genes. Therefore, these 
findings have important clinical implications.
By using genome-wide ChIP-Seq and targeted sequential 
ChIP (ChIP-reChIP), we prove that TERT stabilizes MYC directly 
on chromatin, resulting in increased levels of MYC binding at both 
high-affinity and low-affinity binding promoters (23, 26). Thus, we 
not only provide a unifying reason for TERT reactivation in can-
cers and explain why telomere-independent roles of telomerase 
have been observed, but also explain why MYC and TERT activi-
ties need to coexist in a majority of human cancers. Together with 
previous observations (8–21), our findings provide a fundamen-
tal paradigm shift in the way that TERT ought to be studied, not 
just as a reverse transcriptase subunit but also as a transcriptional 
amplifier in cancers.
Since MYC does not act as a pioneer transcription factor but 
has the ability to bind to its target sequences in a permissive open 
chromatin state, which is preloaded with POL2 (45, 66), it will be 
important to study how MYC will bind to differential targets, as 
the chromatin state of a cell changes during cancer progression. 
Whether these binding events will be a driving step to carcinogen-
esis and whether TERT itself, by acting as a cofactor of other tran-
scription factors (16), will contribute to changing the epigenetic 
state of a cell will also be extremely relevant areas of investigation 
for future research. Small-molecule inhibition of BRD4, used as an 
indirect means to target oncogenic MYC functions, is proving to 
be an exciting new avenue for cancer therapy (67–69). We believe 
that the intersection between the telomerase and the MYC signal-
ing pathways described here will have similarly important thera-
peutic implications. We speculate that our results might lead to the 
development of novel combinatorial cancer treatment modalities. 
In summary, this report, using biochemical and genetic systems, 
shows for what we believe to be the first time that Tert-null mice, 
unlike the Terc-null mice, have delayed onset of MYC-induced 
lymphomagenesis. No other studies to our knowledge have shown 
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fragmented chromatin was precleared with BSA and protein A Sephar-
ose beads (Millipore) at 4°C for 2 hours before immunoprecipitation 
with TERT, c-MYC, or rabbit control IgG antibodies overnight at 4°C. 
The sepharose beads were washed as described above and eluted with 
SDS elution buffer before being subjected to reverse cross-linking at 
65°C overnight. Finally, the samples were purified using the QIAquick 
PCR Purification Kit (Qiagen) according to the manufacturer’s proto-
col. This was followed by PCR using the primers listed in Supplemen-
tal Table 3 and DreamTaq Green PCR Master Mix (2X) (Fermentas).
Sequential ChIP was carried out as described above, except that 
prior to the first immunoprecipitation, the first antibody was cross-linked 
to protein A Sepharose beads using disuccinimidyl suberate (Pierce) to 
prevent antibody leaching after the first DNA-protein elution from the 
beads with SDS. After a series of ChIP washes, the beads were eluted 
with SDS elution buffer at 37°C for 45 minutes. The eluate was then 
diluted 20 times before being subjected to a second immunoprecipita-
tion overnight with sepharose beads and the respective second antibody. 
After the second round of immunoprecipitation, the washed beads were 
again eluted with SDS elution buffer but at 65°C for 30 minutes. After 
reverse cross-linking and DNA purification, real-time qPCR was car-
ried out using the SYBR Green PCR Master Mix (Applied Biosystems) 
to determine the amount of DNA enrichment relative to the initial input 
sample after 2 rounds of immunoprecipitation. Normal rabbit IgG was 
included as a second antibody in an independent sequential ChIP exper-
iment as a control for the estimation of the extent of antibody leaching 
prior to second immunoprecipitation with antibody against protein of 
interest. ChIP-Seq was carried out as previously described (72).
ChIP-Seq and expression data analysis. All reads were adapter 
removed and trimmed to 35 bp using trimmomatic (73). Reads from 
P493 and EμMYC samples were mapped to the hg19 and mm10 
genome, respectively, by bowtie v. 2.2.3 (74). Only uniquely mapped 
reads with an alignment score greater than 10 were kept.
reverse-transcriptase reactions performed using the SuperScript VILO 
cDNA Synthesis Kit (Invitrogen). Then, real-time qPCR was performed 
on the synthesized cDNA using SYBR Green PCR Master Mix (Invit-
rogen), and relative gene expression was analyzed with the iCycler 
Thermal Cycler (Bio-Rad). The primers used are listed in Supplemental 
Table 2. Experimental Ct values were normalized to β-actin, and rela-
tive mRNA expression was calculated versus a reference sample.
Coimmunoprecipitation and ubiquitination assay. Cells were 
washed with ice-cold PBS and then lysed in a solution containing 50 
mM Tris, pH 8, 150 mM NaCl, 0.5% NP40, 0.5% deoxycholic acid, 
0.005% SDS, and protease inhibitors for 30 minutes on ice. Cells 
lysates were removed by centrifugation, and the supernatants were 
incubated with anti-TERT or anti-MYC or rabbit anti-IgG overnight 
at 4°C and with protein G magnetic beads (Millipore) for another 2 
hours. The beads were washed 4 times with 500 μl PBS containing 
0.1% Tween 20. The bound proteins were eluted with SDS sample 
buffer and separated by SDS-PAGE gels before immunoblotting 
with the specific antibodies mentioned above.
For His-ubiquitin immunoprecipitation, cells were lysed in solu-
tion containing 8 M urea, 0.5% Triton X-100, and 10 mM imidazole. 
Ni-NTA beads (20 μl, Qiagen) were then added to cell extracts (500 
μg) and incubated for 4 hours at room temperature with rotation. 
Beads were then washed in lysis buffer and boiled in SDS sample buf-
fer and separated by SDS-PAGE gels before immunoblotting with the 
specific antibodies mentioned above.
Telomere length analysis by Teloblot. This was performed as 
described previously (17).
ChIP, sequential ChIP-qPCR, and ChIP-Seq. Cells were treated with 
1% formaldehyde for 10 minutes at room temperature to cross-link 
protein-DNA complexes, and reactions were then quenched using 125 
mM glycine for 5 minutes. The cells were then lysed with SDS lysis buf-
fer and sonicated for 10 minutes using the Diagenode Bioruptor. The 
Figure 7. Graphical model. TERT levels, which limit the reconstitution of telomerase activity in normal cells, are upregulated by increased MYC in cancer cells. 
TERT, in turn, enhances MYC stability and function, thereby regulating its own levels and telomerase activity. This function of TERT does not require Terc and 
is independent of its function at telomeres. Enhanced MYC stability and function in high-TERT and high-MYC cells, a consequence of this feed-forward mech-
anism, lead to enhanced oncogenesis due to downstream targets of MYC, which are known to regulate aspects of cell cycle, proliferation, and metabolism.
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EμMYC Tert+/–, and EμMYC Tert–/– mice. EμMYC and Terc+/– mice 
were crossed to obtain EμMYC Terc+/+, EμMYC Terc+/–, and EμMYC 
Terc–/– mice. To avoid the potential long-term effects of telomere 
shortening seen after several generations of intercrossing Tert–/– or 
Terc–/– mice, the parental genotypes were consistently maintained as 
EμMYC Tert+/–, Tert+/–, EμMYC Terc+/–, and Terc+/–.
Statistics. Student’s t test (2 tailed) or ANOVA with Dunnett’s 
multiple comparison test or Tukey’s multiple comparison test was 
applied, as appropriate. For survival analyses, the Kaplan-Meier 
method was applied, and the curves were compared using the log-
rank test. Changes were considered statistically significant when 
the P values were less than 0.05. The data are presented as the 
mean and standard deviation. The full statistical analysis is shown 
in Supplemental Table 4.
Study approval. The experimental protocol was approved by the 
Institutional Animal Care and Use Committee, Biological Resource 
Center, A*STAR, and the animals were maintained under compliance 
with A*STAR’s institutional guidelines.
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Peaks were identified by MACS 2.0.10 (75) with parameters 
“nomodel,” shift size 100, and a maximum of 3 reads per unique 
position. Only highly enriched (greater than 5-fold enrichment 
over background) and highly significant (–log10 q value of greater 
than 30) peaks were used for the analysis, yielding 151 (shTERT), 
3,532 (shTerc), 5,159 (shControl), 831 (EμMYC Tert–/–), and 3,584 
(EμMYC Tert+/+) peaks.
The expression data from triplicate Illumina HumanHT 12 V4 
microarrays from shControl and shTERT1 P493 cells were quantile 
normalized using the beadarray package in R (76) and filtered for 
probes flagged as “missing” using ReMOAT (77), and only probes 
with a detection P value of less than 0.01 in at least one sample were 
considered to be detected above background. In total, 2,863 and 
2,605 probes were significantly upregulated and downregulated, 
respectively, at a FDR of less than 1%.
To compare expression and binding data, raw read counts 
within 500 bp around RefSeq promoters were calculated, normal-
ized to total map mass, and background subtracted using the Trans-
View package in R.
Gene Ontology (GO) analysis was performed using Database for 
Annotation, Visualization and Integrated Discovery (DAVID) software 
tools (http://david.abcc.ncifcrf.gov/home.jsp). GO functional anno-
tation analysis with DAVID tools was performed using the GO term 
“biological processes” (BP-FAT). GO clusters with a minimal enrich-
ment of 2-fold at a FDR of less than 1% were considered to be signifi-
cantly enriched.
The ChIP-Seq and microarray experiments were deposited into 
the NCBI GEO database, with the accession number GSE60224.
Animal studies. All mice were monitored daily for signs of mor-
bidity and lymphoma development. EμMYC (strain C57/BL6); 
Tert+/– and Terc+/– (origin strain STOCK 129/Sv and C57BL/6J and 
SJL); and C57BL/6 mice were purchased from The Jackson Labo-
ratory. No backcrossing was done. For lymphoma reconstitution 
studies, C57BL/6 recipient mice were transplanted with 106 EμMYC 
lymphoma cells by tail vein injection, as previously described (70). 
EμMYC and Tert+/– mice were crossed to obtain EμMYC Tert+/+, 
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